Botanix Pharmaceuticals (BOT) Status Update Presentation summary

Sofdra launch performance and demand

• Over 16,000 prescriptions filled for 6,700 patients since February 2025 launch, with more than 2,300 unique prescribers in June and refill rates exceeding industry averages.

• Gross sales reached $25 million AUD from January to June 2025, increasing month over month, with strong TRx growth and expanding prescriber base.

• 95% adherence rate among auto-refill patients and 79% among all patients, with average fills per patient surpassing industry benchmarks.

• Strategic investments in sales force expansion and comprehensive HCP/patient engagement programs are driving further demand.

• Recent publication of phase 3 data in JAAD and medical education initiatives support product credibility and prescriber engagement.

Profitability and gross-to-net (GTN) performance

• Gross-to-net yield improved to 23% by June 2025, with a target of 30–40% as reimbursement rates rise and deductible season ends.

• Fully reimbursed claims increased by ~50% since launch, while high-deductible claims dropped ~75%, and non-reimbursed claims declined steadily.

• Early $0 copay program accelerated patient adoption, with 70% of PA pending units eventually reimbursed.

• GTN performance is tracking in line with or ahead of recent successful dermatology launches.

• Refill growth and improved PA pull-through are expected to further enhance GTN and net revenue.

Strategic growth initiatives and market expansion

• Sales force expanded from 27 to 50 territories across three phases in 2025–2026, covering more regions and increasing reach.

• Comprehensive HCP engagement includes in-office materials, speaker programs, special events, and digital media to drive awareness and adoption.

• Consumer marketing and telehealth initiatives enable easy patient access and support refill adherence.

• Focus for 2H 2025 is on increasing PA approvals and fully reimbursed prescriptions, leveraging growing prescriber base.

• Continued investment in medical communications and education to reinforce clinical value and support prescriber confidence.